Overview

An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of simeprevir in combination with sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of participants with sustained virologic response at 12 weeks after end of treatment (SVR12) in the overall population.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen-Cilag International NV

Treatments:

Simeprevir
Sofosbuvir